Nicox SA
Company Profile
Business description
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
Contact
Rue Evariste Galois
Emerald Square, Batiment C
Sundesk Sophia Antipolis
Biot06410
FRAT: +33 497245300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
stocks
Chart of the Week: This ASX top pick might be overlooked
stocks
ASX share undervalued as margins expected to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.80 | 39.10 | -0.43% |
| CAC 40 | 8,461.89 | 31.10 | 0.37% |
| DAX 40 | 25,025.91 | 91.24 | 0.37% |
| Dow JONES (US) | 51,725.03 | 232.48 | 0.45% |
| FTSE 100 | 10,396.29 | 112.32 | -1.07% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,373.04 | 351.38 | 1.35% |
| Nikkei 225 | 71,053.49 | 1,151.24 | 1.65% |
| NZX 50 Index | 13,363.31 | 29.67 | -0.22% |
| S&P 500 | 7,493.12 | 73.02 | 0.98% |
| S&P/ASX 200 | 8,911.10 | 37.60 | -0.42% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |